Try our beta test site
277 studies found for:    regeneron
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Condition: Dermatitis, Atopic
Interventions: Drug: dupilumab;   Drug: placebo
2 Completed Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
Condition: Neovascular Age Related Macular Degeneration
Interventions: Drug: VEGF Trap;   Biological: VEGF Trap
3 Withdrawn A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: REGN475;   Other: Placebo
4 Withdrawn Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury
Condition: Thermal Injury Pain
Interventions: Drug: R475;   Drug: Placebo
5 Withdrawn Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
Conditions: Chronic Kidney Disease;   Anemia
Intervention: Drug: Rilonacept
6 Completed Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema
Condition: Diabetic Macular Edema
Intervention: Drug: VEGF Trap-Eye
7 Not yet recruiting Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions: Carcinoma,Non-Small-Cell Lung;   Lung Carcinomas, Non-Small-Cell;   Non-small-cell Lung Carcinoma;   Nonsmall Cell Lung Cancer
Interventions: Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: REGN2810
8 Not yet recruiting Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis
Conditions: Moderate-to-Severe Atopic Dermatiti;   Dermatitis, Dermatitis Atopic;   Eczema, Skin Diseases, Skin;   Diseases Genetic, Genetic;   Diseases Inborn, Skin;   Disease, Eczematous Skin;   Hypersensitivity, Immediate;   Hypersensitivity, Immune System Diseases;   Dermatitis, Atopic
Interventions: Drug: Dupilumab;   Drug: Placebos
9 Not yet recruiting Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
Conditions: Atopic Disorders;   Eczema, Atopic
Interventions: Drug: Dupilumab;   Device: Auto-injector Device;   Device: Prefilled syringe
10 Recruiting Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Condition: Malignancies
Interventions: Drug: REGN3767;   Drug: REGN2810
11 Recruiting Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma
Conditions: Asthma;   Moderate Asthma
Interventions: Drug: REGN3500;   Drug: Placebo
12 Recruiting Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo
Condition: Hypercholesterolemia
Interventions: Drug: Praluent (Alirocumab);   Drug: Placebo
13 Recruiting Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women
Condition: Healthy Volunteers
Interventions: Drug: REGN1033;   Drug: REGN2477;   Other: Placebo
14 Recruiting Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Condition: Advanced Cutaneous Squamous Cell Carcinoma
Intervention: Drug: REGN2810
15 Recruiting Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Condition: Nonproliferative Diabetic Retinopathy
Interventions: Drug: Intravitreal aflibercept injection [IAI];   Drug: Sham
16 Recruiting Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Condition: Osteoarthritis of the Knee or Hip
Interventions: Drug: Fasinumab;   Drug: Placebo
17 Recruiting Study of REGN2810 and REGN1979 in Patients With Lymphoma or Acute Lymphoblastic Leukemia
Conditions: Lymphoma;   Acute Lymphoblastic Leukemia
Interventions: Drug: REGN2810;   Drug: REGN1979
18 Recruiting Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Advanced Malignancies
Interventions: Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: GM-CSF;   Drug: Paclitaxel;   Drug: Pemetrexed
19 Recruiting A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
Conditions: Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia
Intervention: Drug: REGN1979 multiple dose levels
20 Completed Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)
Condition: Atopic Dermatitis
Interventions: Drug: Dupilumab;   Drug: Midazolam;   Drug: Omeprazole;   Drug: Warfarin;   Drug: Caffeine;   Drug: Metoprolol

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.